{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:34:41Z","timestamp":1793003681700,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe immune-related adverse events (irAE) in cancer patients receiving immune checkpoint inhibitors (ICI) require treatment interruption and immunosuppression. Based on prior preclinical data, in this prospective, single arm, non-randomized phase-Ib\/II clinical trial we test the activity of Extracorporeal Photopheresis (ECP) against steroid-refractory irAEs in 30 patients (EudraCT-No.:2021-002073-26). The primary endpoint is the evaluation of the safety of ECP treatment for patients with ICI-induced irAEs. The study meets its pre-specified primary endpoint of less than 50% of patients developing ECP-related severe adverse events (SAE). No ECP-related SAE is observed and ECP-related AEs are reported in 20% (6\/30) of patients. Overall response rate for all irAEs is 96.3% (CI 81.0\u201399.91). Colitis-, hepatitis- and dermatitis-specific response rates are 100% (13\/13), 86.7% (13\/15) and 100% (3\/3), respectively. Secondary endpoints include the assessment of response rate of irAE and overall survival. ECP\u00a0therapy is associated with reduced granzyme-A\/B\/K, T-bet, interferon-\u03b3 and TNF in peripheral T cells and pro-inflammatory gene-expression in the intestinal tract. The 12-month overall survival rate is 84.3% (CI 63.4%-93.8%). Response correlates with a decrease in inflammatory gene expression in the intestinal tract. These results suggest that ECP is a safe treatment option for SR-irAEs and warrant further investigation in subsequent randomized clinical trials.<\/jats:p>","DOI":"10.1038\/s41467-026-78897-9","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:42:51Z","timestamp":1792766571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib\/II clinical trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Roxane","family":"Riemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0770-4994","authenticated-orcid":false,"given":"Lukas M.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8146-2199","authenticated-orcid":false,"given":"Sophie","family":"Giesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7850-3199","authenticated-orcid":false,"given":"David","family":"Rafei-Shamsabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Melchinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Birth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Gebhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schw\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-4210","authenticated-orcid":false,"given":"James A.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Karantzelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-3135","authenticated-orcid":false,"given":"Till","family":"Wallrabenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Lowinus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Brehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Rawluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8095-5287","authenticated-orcid":false,"given":"Natascha","family":"Osswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8558-0347","authenticated-orcid":false,"given":"Peter","family":"Bronsert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-9159","authenticated-orcid":false,"given":"Manuel","family":"Rogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3808-8331","authenticated-orcid":false,"given":"Grigor","family":"Andreev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-0602","authenticated-orcid":false,"given":"Melanie","family":"Boerries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7306-5457","authenticated-orcid":false,"given":"Maximilian","family":"Lammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7502-0431","authenticated-orcid":false,"given":"Natalie","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7325-7753","authenticated-orcid":false,"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-1589","authenticated-orcid":false,"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8307-5267","authenticated-orcid":false,"given":"Philip","family":"Keye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8211-5538","authenticated-orcid":false,"given":"Susana","family":"Minguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-6704","authenticated-orcid":false,"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-4135","authenticated-orcid":false,"given":"Robert","family":"Thimme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hasselblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5592-5439","authenticated-orcid":false,"given":"Erika L.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1541-7867","authenticated-orcid":false,"given":"Burkhard","family":"Becher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Funke-Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9635-5487","authenticated-orcid":false,"given":"Florian","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2552-740X","authenticated-orcid":false,"given":"Bertram","family":"Bengsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Malte","family":"Placke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-9094","authenticated-orcid":false,"given":"Frank","family":"Meiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3856-5109","authenticated-orcid":false,"given":"Petya","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"78897_CR1","doi-asserted-by":"crossref","unstructured":"Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R. & Chandra, A. B. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers 12, 738 (2020).","DOI":"10.3390\/cancers12030738"},{"key":"78897_CR2","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/annonc\/mdz175","volume":"30","author":"J Vansteenkiste","year":"2019","unstructured":"Vansteenkiste, J. et al. Current status of immune checkpoint inhibition in early-stage NSCLC. Ann. Oncol. 30, 1244\u20131253 (2019).","journal-title":"Ann. Oncol."},{"key":"78897_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","volume":"79","author":"N Gaynor","year":"2022","unstructured":"Gaynor, N., Crown, J. & Collins, D. M. Immune checkpoint inhibitors: key trials and an emerging role in breast cancer. Semin. Cancer Biol. 79, 44\u201357 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"78897_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. New Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"New Engl. J. Med."},{"key":"78897_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson, D. B., Nebhan, C. A., Moslehi, J. J. & Balko, J. M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat. Rev. Clin. Oncol. 19, 254\u2013267 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"78897_CR6","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e9","volume":"20","author":"J Choi","year":"2020","unstructured":"Choi, J. & Lee, S. Y. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 20, e9 (2020).","journal-title":"Immune Netw."},{"key":"78897_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"78897_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217\u20131238 (2022).","journal-title":"Ann. Oncol."},{"key":"78897_CR9","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"78897_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jamaoncol.2021.4342","volume":"7","author":"M Li","year":"2021","unstructured":"Li, M. et al. Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer. JAMA Oncol. 7, 1711\u20131714 (2021).","journal-title":"JAMA Oncol."},{"key":"78897_CR11","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41591-019-0566-4","volume":"25","author":"H Yang","year":"2019","unstructured":"Yang, H. et al. Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nat. Med. 25, 1428\u20131441 (2019).","journal-title":"Nat. Med."},{"key":"78897_CR12","doi-asserted-by":"crossref","unstructured":"Hu, X. et al. Inhibition of IL-25\/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. J. Immunother. Cancer 12, e008482 (2024).","DOI":"10.1136\/jitc-2023-008482"},{"key":"78897_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","volume":"43","author":"LM Braun","year":"2025","unstructured":"Braun, L. M. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell 43, 269\u2013291 (2025).","journal-title":"Cancer Cell"},{"key":"78897_CR14","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour, K. C. et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36, 2872\u20132878 (2018).","journal-title":"J. Clin. Oncol."},{"key":"78897_CR15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","volume":"157","author":"M Kostine","year":"2021","unstructured":"Kostine, M. et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur. J. Cancer 157, 474\u2013484 (2021).","journal-title":"Eur. J. Cancer"},{"key":"78897_CR16","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","volume":"27","author":"X Bai","year":"2021","unstructured":"Bai, X. et al. Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin. Cancer Res. 27, 5993\u20136000 (2021).","journal-title":"Clin. Cancer Res."},{"key":"78897_CR17","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje, A. T. et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124, 3706\u20133714 (2018).","journal-title":"Cancer"},{"key":"78897_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho, A. E. & Chapman, K. E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2\u201313 (2011).","journal-title":"Mol. Cell. Endocrinol."},{"key":"78897_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H. & Foster, C. S. Long-term side effects of glucocorticoids. Expert Opin. Drug Saf. 15, 457\u2013465 (2016).","journal-title":"Expert Opin. Drug Saf."},{"key":"78897_CR20","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.7150\/jca.87335","volume":"14","author":"AP Machado","year":"2023","unstructured":"Machado, A. P. et al. The safety of immunosuppressants used in the treatment of immune-related adverse events due to immune checkpoint inhibitors: a systematic review. J. Cancer 14, 2956\u20132963 (2023).","journal-title":"J. Cancer"},{"key":"78897_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10777-w","volume":"12","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard, L. et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci. Rep. 12, 7140 (2022).","journal-title":"Sci. Rep."},{"key":"78897_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MD.0b013e3181e93d00","volume":"89","author":"N Kamanamool","year":"2010","unstructured":"Kamanamool, N. et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine 89, 227\u2013235 (2010).","journal-title":"Medicine"},{"key":"78897_CR23","unstructured":"Busuttil, R. W. & Klintmalm, G. B. Transplantation of the Liver (W.B. Saunders, 2015)."},{"key":"78897_CR24","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","volume":"26","author":"RJ Verheijden","year":"2020","unstructured":"Verheijden, R. J. et al. Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry. Clin. Cancer Res. 26, 2268\u20132274 (2020).","journal-title":"Clin. Cancer Res."},{"key":"78897_CR25","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","volume":"8","author":"OJ van Not","year":"2022","unstructured":"van Not, O. J. et al. Association of immune-related adverse event management with survival in patients with advanced melanoma. JAMA Oncol. 8, 1794\u20131801 (2022).","journal-title":"JAMA Oncol."},{"key":"78897_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003277","volume":"9","author":"F Zou","year":"2021","unstructured":"Zou, F. et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J. Immunother. Cancer 9, e003277 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"78897_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih, H. et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J. Immunother. Cancer 6, 142 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"78897_CR28","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1111\/ajco.12651","volume":"13","author":"NT Hillock","year":"2017","unstructured":"Hillock, N. T., Heard, S., Kichenadasse, G., Hill, C. L. & Andrews, J. Infliximab for ipilimumab-induced colitis: a series of 13 patients. Asia Pac. J. Clin. Oncol. 13, e284\u2013e290 (2017).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"78897_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3892\/mco.2021.2227","volume":"14","author":"Y Kadokawa","year":"2021","unstructured":"Kadokawa, Y. et al. Efficacy and safety of infliximab for steroid-resistant immune-related adverse events: a retrospective study. Mol. Clin. Oncol. 14, 65 (2021).","journal-title":"Mol. Clin. Oncol."},{"key":"78897_CR30","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000508479","volume":"47","author":"PA Vieyra-Garcia","year":"2020","unstructured":"Vieyra-Garcia, P. A. & Wolf, P. Extracorporeal photopheresis: a case of immunotherapy ahead of its time. Transfus. Med. Hemotherapy 47, 226\u2013235 (2020).","journal-title":"Transfus. Med. Hemotherapy"},{"key":"78897_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1056\/NEJMc1912274","volume":"382","author":"P Apostolova","year":"2020","unstructured":"Apostolova, P. et al. Extracorporeal photopheresis for colitis induced by checkpoint-inhibitor therapy. New Engl. J. Med. 382, 294\u2013296 (2020).","journal-title":"New Engl. J. Med."},{"key":"78897_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/CJI.0000000000000510","volume":"47","author":"T Ruf","year":"2024","unstructured":"Ruf, T. et al. Extracorporeal photopheresis as a treatment option for immune-related adverse events: two case reports and a prospective study. J. Immunother. 47, 227\u2013231 (2024).","journal-title":"J. Immunother."},{"key":"78897_CR33","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1182\/blood-2023-173575","volume":"142","author":"E Gavriilaki","year":"2023","unstructured":"Gavriilaki, E. et al. Safety and efficacy of extracorporeal photopheresis for acute and chronic graft-versus-host-disease. Blood 142, 7006\u20137006 (2023).","journal-title":"Blood"},{"key":"78897_CR34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jtct.2023.07.001","volume":"29","author":"P Asensi Cant\u00f3","year":"2023","unstructured":"Asensi Cant\u00f3, P., Sanz Caballer, J., Solves Alca\u00edna, P., de la Rubia Comos, J. & G\u00f3mez Segu\u00ed, I. Extracorporeal photopheresis in graft-versus-host disease. Transplant. Cell. Ther. 29, 556\u2013566 (2023).","journal-title":"Transplant. Cell. Ther."},{"key":"78897_CR35","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41375-022-01701-2","volume":"36","author":"HT Greinix","year":"2022","unstructured":"Greinix, H. T., Ayuk, F. & Zeiser, R. Extracorporeal photopheresis in acute and chronic steroid\u2011refractory graft-versus-host disease: an evolving treatment landscape. Leukemia 36, 2558\u20132566 (2022).","journal-title":"Leukemia"},{"key":"78897_CR36","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1182\/blood-2023-191313","volume":"142","author":"N Dong","year":"2023","unstructured":"Dong, N. et al. A retrospective study of extracorporeal photopheresis (ECP) in treatment of cutaneous T-cell lymphoma (CTCL) evaluating global, skin and blood responses. Blood 142, 3078\u20133078 (2023).","journal-title":"Blood"},{"key":"78897_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/archdermatol.2008.547","volume":"145","author":"JH Neustadter","year":"2009","unstructured":"Neustadter, J. H., Samarin, F., Carlson, K. R. & Girardi, M. Extracorporeal photochemotherapy for generalized deep morphea. Arch. Dermatol. 145, 127\u2013130 (2009).","journal-title":"Arch. Dermatol."},{"key":"78897_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/bjh.14537","volume":"177","author":"A Alfred","year":"2017","unstructured":"Alfred, A. et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br. J. Haematol. 177, 287\u2013310 (2017).","journal-title":"Br. J. Haematol."},{"key":"78897_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115049","volume":"212","author":"C Ertl","year":"2024","unstructured":"Ertl, C. et al. Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: interim analysis of a prospective two-arm study. Eur. J. Cancer 212, 115049 (2024).","journal-title":"Eur. J. Cancer"},{"key":"78897_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1727312","volume":"16","author":"CM Thielmann","year":"2025","unstructured":"Thielmann, C. M. et al. Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients. Front. Immunol. 16, 1727312 (2025).","journal-title":"Front. Immunol."},{"key":"78897_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2015-310187","volume":"66","author":"A Marchal-Bressenot","year":"2017","unstructured":"Marchal-Bressenot, A. et al. Development and validation of the Nancy histological index for UC. Gut 66, 43\u201349 (2017).","journal-title":"Gut"},{"key":"78897_CR42","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655\u2013671 (2020).","journal-title":"Cell"},{"key":"78897_CR43","first-page":"2327","volume":"21","author":"J Stallhofer","year":"2015","unstructured":"Stallhofer, J. et al. Lipocalin-2 is a disease activity marker in inflammatory bowel disease regulated by IL-17A, IL-22, and TNF-\u03b1 and modulated by IL23R genotype status. Inflamm. Bowel Dis. 21, 2327\u20132340 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"78897_CR44","doi-asserted-by":"publisher","first-page":"e002058","DOI":"10.1136\/jitc-2020-002058","volume":"9","author":"F Zou","year":"2021","unstructured":"Zou, F. et al. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immunemediated diarrhea and colitis. J. Immunother. Cancer 9, e002058 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"78897_CR45","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","volume":"161","author":"SC Sasson","year":"2021","unstructured":"Sasson, S. C. et al. Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology 161, 1229\u20131244 (2021).","journal-title":"Gastroenterology"},{"key":"78897_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","volume":"4","author":"NG Nunez","year":"2023","unstructured":"Nunez, N. G. et al. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med 4, 113\u2013129 (2023).","journal-title":"Med"},{"key":"78897_CR47","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2006","unstructured":"Beck, K. E. et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24, 2283\u20132289 (2006).","journal-title":"J. Clin. Oncol."},{"key":"78897_CR48","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S2468-1253(20)30014-5","volume":"5","author":"N Powell","year":"2020","unstructured":"Powell, N. et al. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol. Hepatol. 5, 679\u2013697 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"78897_CR49","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1006\/bbrc.2000.3922","volume":"279","author":"SL Planey","year":"2000","unstructured":"Planey, S. L. & Litwack, G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem. Biophys. Res. Commun. 279, 307\u2013312 (2000).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"78897_CR50","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","volume":"16","author":"J Luo","year":"2021","unstructured":"Luo, J. et al. Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events. J. Thorac. Oncol. 16, 1759\u20131764 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"78897_CR51","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat, T. Z. et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33, 3193\u20133198 (2015).","journal-title":"J. Clin. Oncol."},{"key":"78897_CR52","doi-asserted-by":"crossref","unstructured":"Marschner, D. et al. MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. JCI Insight 5, e132334 (2020).","DOI":"10.1172\/jci.insight.132334"},{"key":"78897_CR53","doi-asserted-by":"crossref","unstructured":"Petrelli, F. et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers 12, 546 (2020).","DOI":"10.3390\/cancers12030546"},{"key":"78897_CR54","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000507579","volume":"5","author":"J Burla","year":"2020","unstructured":"Burla, J. et al. Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor for a steroid-refractory disease course. Inflamm. Intest. Dis. 5, 109\u2013116 (2020).","journal-title":"Inflamm. Intest. Dis."},{"key":"78897_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","volume":"6","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J. Immunother. Cancer 6, 37 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"78897_CR56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih, H. et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer 7, 93 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"78897_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005111","volume":"10","author":"RB Holmstroem","year":"2022","unstructured":"Holmstroem, R. B. et al. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J. Immunother. Cancer 10, e005111 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"78897_CR58","doi-asserted-by":"crossref","unstructured":"Harvey, C. et al. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J. Immunother. Cancer 12, e008232 (2024).","DOI":"10.1136\/jitc-2023-008232"},{"key":"78897_CR59","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.3748\/wjg.v20.i43.16014","volume":"20","author":"NN Andersen","year":"2014","unstructured":"Andersen, N. N. & Jess, T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J. Gastroenterol. 20, 16014\u201316019 (2014).","journal-title":"World J. Gastroenterol."},{"key":"78897_CR60","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.14309\/ajg.0000000000002961","volume":"119","author":"S Karlqvist","year":"2024","unstructured":"Karlqvist, S. et al. Comparative risk of serious infection with vedolizumab vs anti-tumor necrosis factor in inflammatory bowel disease: results from Nationwide Swedish Registers. Am. J. Gastroenterol. 119, 2480\u20132492 (2024).","journal-title":"Am. J. Gastroenterol."},{"key":"78897_CR61","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/blood-2009-11-256040","volume":"116","author":"C Berger","year":"2010","unstructured":"Berger, C. et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 116, 4838\u20134847 (2010).","journal-title":"Blood"},{"key":"78897_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1399-0039.1995.tb02474.x","volume":"46","author":"IM Schmitt","year":"1995","unstructured":"Schmitt, I. M. et al. Increased surface expression of class I MHC molecules on immunogenic cells derived from the xenogenization of P815 mastocytoma cells with 8-methoxypsoralen and long-wavelength ultraviolet radiation. Tissue Antigens 46, 45\u201349 (1995).","journal-title":"Tissue Antigens"},{"key":"78897_CR63","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1158\/0008-5472.CAN-18-0171","volume":"78","author":"A Ventura","year":"2018","unstructured":"Ventura, A. et al. Extracorporeal photochemotherapy drives monocyte-to-dendritic cell maturation to induce anticancer immunity. Cancer Res. 78, 4045\u20134058 (2018).","journal-title":"Cancer Res."},{"key":"78897_CR64","unstructured":"National Cancer Institute, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. (National Cancer Institute, U.S. Department of Health and Human Services, 2017)."},{"key":"78897_CR65","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/path.1914","volume":"208","author":"U Gerlach","year":"2006","unstructured":"Gerlach, U. et al. Centrosome-, chromosomal-passenger- and cell-cycle-associated mRNAs are differentially regulated in the development of sporadic colorectal cancer. J. Pathol. 208, 462\u2013472 (2006).","journal-title":"J. Pathol."},{"key":"78897_CR66","doi-asserted-by":"crossref","unstructured":"Wehrle, J. et al. Personalized treatment selection and disease monitoring using circulating tumor DNA profiling in real-world cancer patient management. Diagnostics 10, 550 (2020).","DOI":"10.3390\/diagnostics10080550"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78897-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78897-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78897-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:04:48Z","timestamp":1793001888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78897-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["78897"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-78897-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A. has received travel support from Pfizer, outside the submitted work. S.L. received a research grant from BMS and advisory board\/speaker invitations from AstraZeneca, Eli Lily, Roche, and Takeda outside of this work. D.S. served as a consultant, advisory board and\/or speaker and has received honoraria from Amgen, Array, Bristol-Myers Squibb, Helsinn, Immunocore, InflarX, Merck Sharp & Dohme, Merck-Serono, Nektar, Novartis, OncoSec, Pfizer, Philogen, Regeneron, Replimune, Sandoz, Sanofi, Sunpharma, 4SC and travel support from Bristol-Myers Squibb, Merck Sharp & Dohme, Merck-Serono, Nektar, Novartis, Pierre Fabre, Sandoz, Sanofi, and 4SC, all outside the submitted work. F.M. served as a consultant and\/or received honoraria from Novartis, Bristol Myers Squibb, Merck Sharp & Dohme, Pierre Fabre, Sanofi Genzyme, and Sunpharma; travel support from Novartis, Sunpharma, and Bristol-Myers Squibb. S.U. declares research support from Bristol Myers Squibb and Merck Serono, speakers and advisory board honoraria from Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, and Novartis, and travel support from Bristol Myers Squibb, Merck Sharp & Dohme, and Pierre Fabre. S.G. has received honoraria from Jazz Pharmaceuticals. B.B. declares honoraria from AstraZeneca, Roche, and Bristol Myers Squibb. C.F.-L. received honoraria and travel support from Therakos\/Mallinckrodt. J.-M.P. served as a consultant and\/or has received honoraria from Bristol-Myers Squibb, Novartis, Sanofi, and received travel support from Bristol-Myers Squibb, Novartis, Pierre Fabre, and Therakos. M.S. has served on a data safety monitoring board (DSMB) paid by Biontech, outside of the submitted work. R.Z. has received honoraria from Novartis, Incyte, Sanofi, Medac, Neovii, and Mallinckrodt\/Therakos. All other authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"11078"}}